HUTCHMED (China) Ltd (STU:H7T1)
€ 16.1 0.5 (3.21%) Market Cap: 2.75 Bil Enterprise Value: 2.08 Bil PE Ratio: 0 PB Ratio: 4.11 GF Score: 64/100

Hutchison China MediTech Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 01:40PM GMT
Release Date Price: €19.4 (-4.90%)
Alec Warren Stranahan
BofA Merrill Lynch, Research Division - Associate

Hello everyone. Welcome to the final day of the 2020 Bank of America Health Care Conference. My name is Alec Stranahan, and I'm an analyst on the biopharma team at Bank of America, along with Geoff Meacham, who is also on the line. This session with Chi-Med will last approximately 30 minutes and will include prepared remarks and slides by the company, followed by some brief Q&A. If you are accessing the event through the Veracast platform, you will have the option to submit questions at any time throughout the session. Your questions will be kept anonymous.

And with that, it's my pleasure to introduce Christian Hogg, CEO of Hutchison China MediTech or Chi-Med. Christian, I'll turn it over to you, and then we can jump into questions with Geoff and I after.

Christian Hogg
Hutchison China MediTech Limited - CEO & Executive Director

I will give a brief maybe 10-, 15-minute status update on Chi-Med

(technical difficulty)

So Page #3 is our global strategy.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot